Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
After publishing: 3 headlines quietly rewritten, 1 description edited, 5 URLs changed9 changes
- South China Morning Postseen 25 Aug, 14:23headline rewritten
As global drug giants grow cautious, can Chinese biotech keep cashing in on out-licensing?As drug giants grow cautious, can Chinese biotech firms still cash in on licensing deals? - prnewswire.comseen 25 Aug, 17:22URL changed
- South China Morning Postseen 27 Aug, 12:17description edited
what the description said, before and after
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharma industry increasingly looks to compete on the global stage. The Chinese trial tested ivonescimab and chemotherapy...Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharmaceutical industry increasingly looks to compete on the global stage. The Chinese trial tested ivonescimab and...
- jcnnewswire.comseen 6 Sept, 02:50URL changed
now resolves towww.jcnnewswire.com/404.aspx
- prnewswire.comseen 21 Sept, 16:05URL changed
- prnewswire.comseen 21 Sept, 16:05URL changed
- finanznachrichten.deseen 23 Sept, 11:01headline rewritten
Biting into high-margin niches; INITIATE with BUY: GHC combines Gerhò's cash-generative dental distribution ...Biting into high-margin niches; INITIATE with BUY: Gallmetzer Healthcare combines Gerhò's cash-generative dental distribution ... - afr.comseen 8 Oct, 07:38headline rewritten
CSL signs drug deal with Swiss biotech giant Alentis Therapeutics to fight rare kidney diseaseCSL could spend up to $2.2b on drug deal with Swiss biotech start-up - jcnnewswire.comseen 9 Oct, 19:50URL changed
now resolves towww.jcnnewswire.com/404.aspx
What it is about
Who published it, and when
+ 45 more outlets
How it spread - 201 original reports, 6 reprints
Wed, 5 August 2026
1 report- manilatimes.net20:30first to report
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ('Biofrontera' or the 'Company'), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.
Thu, 6 August 2026
2 reports- manilatimes.net11:40
Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS1 Parts I, II, and III, as well as a composite endpoint comprising 15 clinically relevant measures.
- manilatimes.net20:56
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (the 'FDA') has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilaris. Aclaris expects to initiate a phased...
Fri, 7 August 2026
1 report- yahoo.com11:05
BioVie used an endpoint called EPNIC-15, which is not well known and only appears to be referenced in papers by the company itself.
Fri, 14 August 2026
5 reports- manilatimes.net12:17
Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026.Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT. MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ('Annovis” or the 'Company”), a Phase 3 clinical-stage...
- manilatimes.net12:17
TUDRIQEV™in combination with nivolumab receives FDA accelerated approval and will launch within 60 days
- manilatimes.net12:17
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
- yahoo.com22:23Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron’s cemiplimab (Libtayo) in patients with solid tumors. BHV-1530’s novel topoisomerase I (TopoIx) payload generates immunogenic cell death and […]
- yahoo.com22:53
On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]
Mon, 17 August 2026
1 report- yahoo.com13:02
Fulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions. Alex S
Tue, 18 August 2026
5 reports- yahoo.com10:38
Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.
- prnewswire.com11:00
/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
- rttnews.com11:03
The following biotech stocks reached a 52-week high on August 17, 2026, driven by key catalysts including prospective clinical trial results and announced acquisitions.
- newswire.ca14:00
/CNW/ -- Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that it successfully completed negotiations with the pan-Canadian Pharmaceutical...
- investegate.co.uk18:15
Comprehensive details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies
Wed, 19 August 2026
1 report- manilatimes.net06:09
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
Fri, 21 August 2026
2 reports- selectscience.net04:30
Harbour BioMed’s HBM7004 IND wins NMPA approval for advanced solid tumors, highlighting novel B7H4xCD3 immunotherapy. Read expert insights on SelectScience.
- finanznachrichten.de13:06
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO)PharmAla has exercised its
Mon, 24 August 2026
1 report- prnewswire.com07:01
/PRNewswire/ -- ImmunoForge (Co-CEOs Sung-Min Ahn and Ki-Ho Chang), a biotech venture specializing in the development of therapeutics for rare diseases,...
Tue, 25 August 2026
7 reports- mondaq.com00:00
FDA-related uncertainty is fundamentally reshaping transaction strategy across the life sciences sector, introducing new complexity into deal structuring and valuation despite strong M&A activity. Shifting regulatory signals, leadership changes, and evolving policy priorities are forcing acquirors to adapt through more creative structuring and strategic, targeted acquisitions.
- manilatimes.net02:40
NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs” or the 'Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to the expansion phase based on encouraging efficacy signals and a favorable safety profile.
- South China Morning Post05:00edited after publishing
previously
As global drug giants grow cautious, can Chinese biotech keep cashing in on out-licensing?Record-breaking cross-border deals helped make some formerly loss-making Chinese biotech companies profitable in the first half of the year, but multinational drugmakers are now signalling plans to tighten deal budgets. Analysts said deals with global partners had overtaken initial public offerings and pre-IPO fundraising as the main funding option for cash-starved Chinese biotech firms wanting to advance the discovery, clinical development and regulatory approval of new drugs. Yet questions...
- manilatimes.net10:03
$400,000 program extends AST-004 into another major CNS indication and reinforces the breadth of its cerebroprotective potential
- chinamoneynetwork.com14:15
Sinobioway Pharmaceutical Group (Hong Kong Stock Exchange Code: 01801), a leading biopharmaceutical company focusing on innovative drugs in the fields of oncology, metabolism, cardiovascular, autoimmune, and ophthalmology diseases, announced its 2026 mid-year performance and the company's 2030 strategic vision. Dr. Yu Dechao, Founder, Chairman, and CEO of Sinobioway Pharmaceutical Group, stated that the company had completed two key transformations in the past fifteen years. The company...
- leaderpost.com14:43
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+
- insidermonkey.com18:28
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) signed an all-stock merger agreement with Slate Medicines that would turn the public company into a migraine-focused biotechnology business.
Wed, 26 August 2026
1 report- rttnews.com14:06
Mabion (MAB) and Oddifact received an FDA Type B pre-IND meeting for RTX-NP (MabionCD20) in immune thrombocytopenia (ITP). The meeting will support regulatory alignment on the program's development strategy and potential BLA submission.
Thu, 27 August 2026
2 reports- South China Morning Post02:07edited after publishing
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharmaceutical industry increasingly looks to compete on the global stage. The Chinese trial tested ivonescimab and...
- miragenews.com12:00
This prospective, multicenter phase II study was conducted across 12 medical institutions in China and registered at ClinicalTrials.gov (NCT05536154
Fri, 28 August 2026
3 reports- insidermonkey.com00:11
The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)
- rttnews.com05:44
Samsung Biologics Co.,Ltd. (207940.KS), a biopharmaceutical contract development and manufacturing organization (CDMO), announced a rights offering expected to raise about KRW 3 trillion to fund its expansion across manufacturing capacity, portfolio and geographic reach.
- clinicalleader.com14:00
Recruiting for rare acute diseases is challenging. Discover how this organization used rapid site activation and investigator engagement to speed enrollment in a Phase III Anti-GBM trial.
Sat, 29 August 2026
4 reports- insidermonkey.com02:28
CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients.
- newswise.com06:45
Phase 2 TRANQUILITY trial results presented by Mount Sinai investigator support further evaluation of pacibekitug in cardiovascular disease
- blayneychronicle.com.au17:30
The federal government has expanded the range of cancers a drug will be subsidised to treat as part...
1 reprint
- cessnockadvertiser.com.au29 Aug, 17:30their copy
- themarketsdaily.com20:20
Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT – Get Free Report) was the target of a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 26,155 shares, an increase of 148.4% from the July 30th total of 10,531 shares. Currently, 2.9% of the shares of the […]
Tue, 1 September 2026
7 reports- healio.com00:00
The FDA has approved the first treatment for essential thrombocythemia in nearly 30 years, according to a PharmaEssentia press release. Ropeginterferon alfa-2b-njft (Besremi, PharmaEssentia Corporation) received approval for adults no matter their genotype or disease status.
- El País (Spain)03:30
El intento de fusión entre AstraZeneca y Bristol Myers evidencia un cambio de ciclo en el sector
- standard-freeholder.com05:04
GHENT, Belgium & TOKYO -- H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II
- finanznachrichten.de09:06
New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research
- finanznachrichten.de15:34
BEDMINSTER, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to JBS-003 (18F-fluoromisonidazole
- prnewswire.com20:05
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
- prnewswire.com20:05
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Wed, 2 September 2026
3 reports- sina.com.hk00:00
Collaboration will use NewBiologix’s Xcell™ platform to establish a scalable manufacturing foundat…
- manilatimes.net01:51
**media[1199190]**The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients.Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement and broaden access to 68Ga-PSMA-PET imaging across a significantly larger patient population.BiPASS is designed to evaluate the diagnostic performance of 68Ga-PSMA-11 PET combined with MRI for...
- Anadolu Agency (AA)22:06
COVID-19 treatment Mprosevir took just 3.5 years from discovery of drug candidate to completion of clinical trials
Thu, 3 September 2026
4 reports- finanzen.ch04:30
(RTTNews) - Today, we bring you a list of six stocks to watch in the coming days and months. Each company has potentially market-moving catalysts ...
- manilatimes.net16:22
Presentations will highlight the clinical utility and long-term commercial opportunity of GENFIT’s proprietary NIS platform, a non-invasive diagnostic technology for MASH Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 3, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it will host a virtual key opinion leader (KOL) event on...
- clinicalleader.com17:45
09/03/26 Clinical Leader Newsletter
- jcnnewswire.com17:45
URL changednow www.jcnnewswire.com/404.aspx
Fri, 4 September 2026
16 reports- bioworld.com00:15
GSK plc is moving further into antibody-drug conjugates, taking ex-China rights to Hutchmed Ltd.’s HMPL-A830 in a deal worth up to $1.295 billion, plus royalties. Of that, GSK is paying $110 million up front for the preclinical asset, which features a dual mode of action, linking an anti-epidermal growth factor receptor (EGFR) antibody to a small-molecule KRAS inhibitor payload. The product is designed to deliver the inhibitor directly to EGFR-expressing tumors and to simultaneously block EGFR...
- finanznachrichten.de01:34
-4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with
- manilatimes.net11:52
Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate.
- manilatimes.net12:12
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ('RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin)...
- manilatimes.net12:13
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET.
- manilatimes.net12:13
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common...
- manilatimes.net12:13
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
- manilatimes.net12:13
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
- manilatimes.net12:13
AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ('Rein') (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.
- clinicalleader.com13:00
09/04/26 Clinical Leader Newsletter
- finanznachrichten.de14:38
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus
- miragenews.com19:15
The World Health Organization (WHO) has issued its first-ever invitation for expression of interest for manufacturers of childhood cancer medicines
- manilatimes.net20:19
BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio’s common stock and restricted stock units ('RSUs”) representing the right to receive an aggregate of 17,900 shares of Vor Bio’s common stock to 6 newly hired employees....
- manilatimes.net20:39
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2026 (the 'Grant Date”), ORIC granted a total of 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees who began their employment with ORIC in August 2026.
- manilatimes.net21:19
BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the 'Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the 'Notice”) from the NYSE American LLC (the 'NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the 'Company Guide”) requiring a company to have stockholders’ equity of at least...
- manilatimes.net23:20
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke,...
Mon, 7 September 2026
1 report- rttnews.com13:56
Roivant (ROIV), a commercial-stage biopharmaceutical company, and its subsidiary, Pulmovant, announced that results from the Phase 2 PHocus study of Mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 on Tuesday, September 8, 2026.
Tue, 8 September 2026
5 reports- bioxconomy.com12:17
Moonwalk Biosciences has closed a $70 million Series B to push adipose-targeted RNAi obesity candidate into the clinic.
- investegate.co.uk12:45
Comprehensive details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies
- rttnews.com14:46
enGene Therapeutics reported a third-quarter 2026 net loss of $32.5 million, or $0.47 per share, compared with $29.0 million, or $0.57 per share, in Q3 2025. The company had $266.
- rttnews.com15:06
Can-Fite BioPharma reported a first-half 2026 net loss of $4.60 million, or $1.24 per share, compared with $4.87 million, or $4.29 per share, in H1 2025. The company highlighted longer-than-anticipated survival in its Phase III liver cancer study of Namodenoson and is evaluating earlier interim analysis.
- rttnews.com18:43
Five biotech stocks were in focus Tuesday. Bluejay Diagnostics gained on a federal healthcare partnership with Lovell Government Services, while Pharvaris advanced after positive Phase 3 CHAPTER-3 results.
Wed, 9 September 2026
3 reports- South China Morning Post09:27
Biomedicine is set to feature in Hong Kong’s first five-year plan, due to be unveiled next week, as the city’s top officials signal closer medical cooperation across the Greater Bay Area. Lending weight to those ambitions, global pharmaceutical company GSK emphasised its interest in expanding its role in the region’s biotech development on Wednesday, at the fifth Hong Kong International Biotechnology Conference and Exhibition (BIOHK). Speaking at the event, Hong Kong Secretary for Health Lo...
- thehindubusinessline.com13:53
Global Healthcare Leaders Back iKure's USD 1.8 Million Pre-Series A to Scale Technology-Enabled Primary Healthcare Across India
- thehindubusinessline.com15:01
CEPI invests $8.9 million in Pune's Immunoscript to develop innovative, freezer-free RNA vaccines for low-resource settings.
Thu, 10 September 2026
3 reports- prnewswire.com11:00
/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
- prnewswire.com11:00
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
- finanznachrichten.de13:26
Calgary, Alberta--(Newsfile Corp. - September 10, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms
Fri, 11 September 2026
2 reports- intelligencer.ca13:04
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762
1 reprint
- recorder.ca11 Sept, 13:04their copy
- tickerreport.com16:14
Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations. Profitability This table compares Mereo BioPharma […]
1 reprint
- dailypolitical.com11 Sept, 13:15their copy
Sat, 12 September 2026
1 report- prnewswire.com09:15
/PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced an abstract for iza-bren (izalontamab brengitecan), a...
Mon, 14 September 2026
2 reports- South China Morning Post04:59
British pharmaceutical company GSK is turning to patient data gathered from the 88 million residents of the Greater Bay Area’s 11 cities to speed up drug development in vaccines and cancer care, as officials push for closer cross-border medical cooperation. GSK Hong Kong and Macau general manager Nicholas Teo said patient data was very important because it could form “supplementary evidence” to support regulatory filings and potential label expansions, and also help to “discover benefits...
- Google News - Europe query10:30
Multi4 Medical Publishes Landmark Clinical Study in Prestigious BJUI - Initiates First Patient Treatments in Europe Yahoo Finance
Wed, 16 September 2026
3 reports- South China Morning Post02:00
British pharmaceutical giant GSK has agreed to acquire a cancer drug from Chinese firm Chimagen Biosciences in a deal worth up to US$750 million, underscoring China’s emergence as a global player in biotechnology. GSK announced plans on Tuesday to buy full global rights to a “potential best-in-class” T-cell engager (TCE) from Chengdu-based Chimagen, targeting treatment for multiple myeloma, a type of blood cancer. TCEs work by binding T cells, a kind of white blood cell, directly to cancer...
- rttnews.com05:21
The following biotech stocks reached a 52-week high on September 15, 2026, driven by the gain on certain clinical or financial results. MediciNova Inc. (MNOV) MediciNova functions as a clinical-stage biopharmaceutical company developing a late-stage pipeline of novel, small-molecule therapeutics for inflammatory, fibrotic, and neurodegenerative diseases.
- standard-freeholder.com20:08
VANCOUVER, British Columbia -- AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International
1 reprint
- thestarphoenix.com16 Sept, 20:08their copy
Thu, 17 September 2026
1 report- intelligencer.ca12:32
TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology
Fri, 18 September 2026
2 reports- South China Morning Post08:00
China has set its sights on becoming a global biomedicine powerhouse by 2030, targeting key technological breakthroughs and at least a quarter of the world’s first-in-class drugs market under a new five-year plan for the sector. By the end of the decade, China would “firmly rank at the global forefront” in biopharmaceutical research and development and applications, with its “core competitiveness” and international influence making a significant leap, authorities said on Friday. The...
- pharmaceuticalonline.com17:15
Mon, 21 September 2026
4 reports- thailand-business-news.com00:30
SINGAPORE, Sept. 21, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia. Ruxolitinib (1.5%) cream…
- finanznachrichten.de08:55edited after publishing
previously
Biting into high-margin niches; INITIATE with BUY: GHC combines Gerhò's cash-generative dental distribution ...Gallmetzer HealthCare (GHC) offers multiple avenues for organic growth and margin expansion. The company is a vertically integrated dental healthcare platform combining a resilient, cash-generative distribution
- 247wallst.com15:45
A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is moving markets and what it signals about what that dataset might show.
- panorama.am16:15
Russian medical laboratory chain HELIX has officially entered the Armenian market, opening a new laboratory complex in Yere
Tue, 22 September 2026
2 reports- intelligencer.ca13:30
Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric Cancer
- iberonews.com14:15
Wed, 23 September 2026
7 reports- South China Morning Post02:00
China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts. US lawmakers and officials at the Food and Drug Administration (FDA) have raised the alarm about American pharmaceutical companies’ growing reliance on conducting early clinical trials in China, flagging the opaqueness of the process and the need to keep...
- sleepreviewmag.com04:41
HoneyNaps has registered as a CRO to expand its FDA-cleared SOMNUM Clinical service, offering AI-powered polysomnography analysis for global trials.
- insidermonkey.com10:26
Beneath the headline-driven sentiment of biotech investing lies the true engine of value creation: portfolio durability, capital efficiency, and sustainable revenue compounding.
- insidermonkey.com10:32
In the high-stakes realm of clinical-stage biotechnology, long-term shareholder value is fundamentally forged by pipeline assets that solve deep-seated clinical bottlenecks while offering significant ...
- insidermonkey.com11:14
When biotechnology innovators approach the commercialization cliff, market participants must weigh the clinical promise of a lead asset against the stark realities of surging operating expenses and capital...
- manilatimes.net11:48
Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up
- finanznachrichten.de21:42
Cash balance of €26.9 million as of June 30, 2026, before tax credits and grants under the France 2030 plan Focus on strategy execution and rigorous program implementation in LCAT Deficiency
Thu, 24 September 2026
2 reports- prnewswire.com11:05
/PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
- prnewswire.com11:09
/PRNewswire/ -- Jetstream Venture Fund (Jetstream), an innovative interval fund dedicated to opening access to institutional-grade deal flow for a wider...
Fri, 25 September 2026
1 report- finanzen.ch05:30
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - https://www.globenewswire.com/Tracker?data=rUiAfdP3vDPo7cm0K...
Sat, 26 September 2026
1 report- South China Morning Post01:00
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion. InnoCare said it would use...
Mon, 28 September 2026
3 reports- sina.com.hk05:45
DKSH and Grünenthal have entered into a new regional partnership agreement covering eight Asia-Paci…
- proactiveinvestors.com09:14
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in...
- ibtimes.com.au14:03
Kodiak Sciences shares surged 143% after the biotech said Zenkuda and tabirafusp-ted met key Phase 3 goals in wet age-related macular degeneration, though full data and regulatory review remain pending.
Tue, 29 September 2026
3 reports- prnewswire.com07:00
/PRNewswire/ -- Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced the...
- South China Morning Post09:00
Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca...
- manilatimes.net15:11
Client-validated case study recognizes AI-enabled menu development platform that transforms gategroup’s document-driven menu creation and frees chefs to focus on their craft
Wed, 30 September 2026
1 report- South China Morning Post06:30
–
Thu, 1 October 2026
19 reports- South China Morning Post08:00
Hong Kong can attract more global biotech investments if the city builds up a new healthcare financial model, according to AstraZeneca, a Cambridge-based multinational pharmaceutical giant. While global drug makers have been doubling down on investments in mainland China in recent years, AstraZeneca brought over 60 clinical trials to the city and invested over HK$200 million (US$25.5 million) over the past three years. Hong Kong was still a key research and development hub for the firm, David...
- Google News - Top Stories09:31
A Cancer Test Has Investors Betting Big. But Will Insurers Pay? WSJ Blood Test That Screens For Multiple Cancers Shows Promise In 36K Person Trial MindBodyGreen This Stock, Up Almost 70%, May Have Found Cancer's Holy 'Grail' Investor's Business Daily 'A groundbreaking finding': Multi-cancer blood test could be available to the public next year KGW Joel Helmke: The Acceleration of Discovery Is Transforming Cancer Care Oncodaily
- manilatimes.net11:19
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026.
- manilatimes.net11:19
Leader in Global Drug Development of T Cell Therapies
- manilatimes.net11:19
Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologies
- manilatimes.net11:19
BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, 'Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.
- manilatimes.net11:19
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation
- manilatimes.net11:19
Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platformPipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass.,...
- manilatimes.net11:19
- RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first half of 2028 -
- manilatimes.net11:19
Board additions bring diabetes-development and company-building expertise as Caspian prepares KO-7246 for advancement into clinical testing
- manilatimes.net11:19
MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ('Unicycive” or the 'Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Meredith Manning, M.B.A., to its Board of Directors.
1 reprint
- finanznachrichten.de1 Oct, 13:12their copy
- insidermonkey.com18:57
September 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launches TAMPA, FL - DataMeds AI, Inc.
- manilatimes.net20:18
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the 'Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units ('RSUs”) to one newly hired employee.
- manilatimes.net20:18
RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that five abstracts will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, taking...
- manilatimes.net20:18
WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on September 30, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule...
- manilatimes.net20:18
PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the 'Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company’s executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in...
- manilatimes.net20:18
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that, in connection with its upsized initial public offering of its common stock, the underwriters have fully exercised their option to purchase an additional 3,937,500 shares of ADARx’s common stock at a price to the public of $17.00 per share. The issuance of the additional shares closed on...
- manilatimes.net20:38
BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the '2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee...
- manilatimes.net20:38
FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose, in lieu of shares of Series A common stock, pre-funded warrants to...
Fri, 2 October 2026
6 reports- neurologyadvisor.com12:30
FDA grants Priority Review to fenebrutinib NDA for RMS and PPMS based on phase 3 trial data showing significant relapse and progression reductions.
- Google News - Europe query12:35
Orano Med Inaugurates ATLab Valenciennes, Europe’s First Industrial Facility Dedicated to the Production of Lead-212-Based Targeted Alpha Therapies Yahoo Finance
- equitybulls.com15:15
Sun Pharmaceutical Industries Limited has presented long-term Phase 3 clinical trial data for LEQSELVI (deuruxolitinib) at the 2026 European Academy of Dermatology and Venereology (EADV) Congress.
- jcnnewswire.com15:15
URL changednow www.jcnnewswire.com/404.aspx
- equitybulls.com15:15
Viyash Scientific Limited has announced the successful completion of its acquisition of BioForLife Italia S.r.l. (BFL Italy).
- clinicalleader.com15:15
A wave of late-stage radiopharmaceutical trials is straining lab infrastructure concentrated in a handful of academic centers, limiting site diversity, expertise, and trial capacity nationwide.
Sat, 3 October 2026
1 report- Google News - Europe query11:05
Orano Med Inaugurates ATLab Valenciennes, Europe’s First Industrial Facility Dedicated to the Production of Lead-212-Based Targeted Alpha Therapies BioSpace
Sun, 4 October 2026
3 reports- manilatimes.net23:10
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared
- manilatimes.net23:18
The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease
- afr.com23:40edited after publishing
previously
CSL signs drug deal with Swiss biotech giant Alentis Therapeutics to fight rare kidney disease
Mon, 5 October 2026
1 report- world-nuclear-news.org12:45
An opening ceremony has been held for Europe's first industrial-scale facility for the production of lead-212-based targeted alpha therapies, the Alpha Therapy Laboratory in Valenciennes, France. ;
Tue, 6 October 2026
3 reports- Google News - Europe query11:02
Key data from Ocugen's three gene therapy programs for blindness are expected in 2027 and 2028. Stock Titan
- themarketsdaily.com16:02
What happened Kamada Ltd. (NASDAQ: KMDA) said on October 6, 2026, that it launched two additional biosimilar products in Israel. The new products are Ustekinumab-Kamada, a biosimilar to Stelara for plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane. Kamada said Enoxaparin-Kamada is for prevention and treatment of thromboembolic […]
- northernnews.ca20:39
BL1243 (tonabersat) is being developed as a potential oral treatment for patients with earlier-stage dry AMD, where treatment options remain limited
Wed, 7 October 2026
7 reports- acs.org00:00
Companies at the CPHI pharmaceutical ingredient convention say demand remains strong
- South China Morning Post04:20
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas. New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib failed to meet its main goal in a phase 3 trial. Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals to treat non-small...
- manilatimes.net06:02
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease inPREDICT-1 registrational symptoms trial on track for topline readout around year-end
- rttnews.com11:25
The following biotech stocks reached a 52-week high on October 6, 2026, driven by key catalysts such as newly announced research collaborations. Pacific Biosciences of California Inc.
- americanbazaaronline.com11:25
Indian firm’s endowment will fund academic leadership in dermatology in perpetuity, supporting research, education and mentorship.
- brantfordexpositor.ca13:04
VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a
1 reprint
- thesudburystar.com7 Oct, 13:04their copy
- abladvisor.com13:45
Rocket Pharmaceuticals, a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, entered into a credit facility agreement with Hercules Capital for up to $150 million. The facility strengthens Rocket’s financial position and provides...
Thu, 8 October 2026
3 reports- chinadaily.com.cn01:11
Under the background of the "Healthy China 2030" strategy, China's biopharmaceutical industry is gradually shifting from an "innovation follower" to a "source of innovation", with more and more Chinese companies stepping onto the world stage, said a senior executive of German life science company Bayer AG.
- finanzen.ch09:59
(RTTNews) - The following biotech stocks reached a 52-week high on October 6, 2026, driven by catalysts such as achieving new regulatory milestone...
- fool.com16:15
BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.
Sat, 10 October 2026
1 report- medicaldaily.com19:18
Caribou Biosciences is ending its off-the-shelf CAR-T programs after failing to fund a phase 3 lymphoma trial. What patients should know.
Sun, 11 October 2026
1 report- South China Morning Post02:15
Hong Kong biotech entrepreneur Ricky Chiu Yin-to is seeking to make cervical cancer screening easier through urine-based HPV testing, using sample-concentration technology developed by his company. His company, Phase Scientific, made its name during the Covid-19 pandemic through its rapid antigen test, Indicaid. The product received US emergency-use authorisation in July 2021, was used in Hong Kong community testing and sold in more than 30 countries. At the start of the pandemic, the firm...
Mon, 12 October 2026
5 reports- rttnews.com07:28
Foresee Pharmaceuticals (6576.TWO) said it was notified by licensing partner, Changchun GeneScience Pharmaceutical, that China's National Medical Products Administration has approved the Marketing Authorization Application for CAMCEVI 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for the treatment of adult patients with advanced prostate cancer.
- rttnews.com07:50
Nanjing Leads Biolabs Co., Ltd. (9887.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to opamtistomig (LBL-024), its investigational antibody, for the first-line treatment of advanced or metastatic biliary tract cancer (BTC).
- rttnews.com07:54
First Tracks Biotherapeutics (TRAX) plans to release and discuss Phase 1b results for ANB033, its CD122-blocking antibody candidate for celiac disease, during an investor webcast on October 12, 2026, at 8:30 a.
- ajmc.com17:24
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
- thewhig.com20:08
New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near
Tue, 13 October 2026
9 reports- manilatimes.net11:44
**media[1257445]**CHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) will present results from multiple clinical studies at the congress, including data from its trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as...
- manilatimes.net11:51
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical...
- manilatimes.net11:51
BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay” or the 'Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol.
- manilatimes.net11:51
Professor Philip Molyneaux will present on the patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)
- manilatimes.net11:51
WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the 'Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that members of its management team will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on...
- manilatimes.net11:51
- EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity -
- prnewswire.com12:13
Randomized, placebo-controlled study in 16 cognitively unimpaired participants met safety and immunogenicity objectives; all 12 vaccine recipients developed...
- investegate.co.uk12:30
Comprehensive details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies
- tickerreport.com19:15
Wed, 14 October 2026
3 reports- timminspress.com08:14
SAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to
- finanznachrichten.de17:48
Study demonstrated 93.3% sensitivity, 92.4% specificity and 99.9% negative predictive value for eyonis LCS eyonis LCS is the first and only FDA-cleared AI/ML-based Software as a Medical Device
- timminspress.com22:28
Milestone follows nearly US$7 million in seed investment and strategic support from SOLVE FSHD VANCOUVER, British Columbia -- SOLVE FSHD, a
Thu, 15 October 2026
3 reports- intelligencer.ca12:09
Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trialThe Company has a
- intelligencer.ca12:13
A case study presented at Child Neurology Society Annual Meeting demonstrates preservation of neurological function in sisters with infantile-onset
- prnewswire.com12:25
/PRNewswire/ -- SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, today announced U.S. Food and Drug...
Sat, 17 October 2026
1 report- themarketsdaily.com18:03
Solid Biosciences (NASDAQ:SLDB – Get Free Report) was upgraded by stock analysts at UBS Group to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks reports. A number of other research analysts have also recently commented on SLDB. Cantor Fitzgerald upped their price objective on Solid Biosciences from $16.00 to $26.00 […]
Sun, 18 October 2026
1 report- aol.com21:33
The company's expertise in gene editing could lead to more breakthroughs.
Mon, 19 October 2026
16 reports- manilatimes.net03:55
SHANGHAI, Oct. 19, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, 'BFv') in locally advanced or metastatic triple-negative breast cancer (TNBC) as an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress. The study focuses on patients previously treated...
- manilatimes.net05:17
Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancerPatient-reported outcomes from phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancerPhase III results in Chinese patients with metastatic...
- manilatimes.net05:18
Press release - No. 21 / 2026
- manilatimes.net05:18
Expansion of nebaprubart (JJP-1212) into RA follows positive interim data from its ongoing Phase 1b trial in linear IgA dermatosis (LAD), marking the second indication for the Company’s lead assetand expanding clinical validation of the IgA/CD89 pathwayWarsaw, Poland - October 19, 2026 - JJP Biologics, ('JJPBio' or the 'Company') a clinical-stage, immune-focused biotechnology company advancing first-in-class therapies for immune-mediated diseases and cancer, today announces that the first...
- econotimes.com11:11
The U.S. Food and Drug Administration identified complaint-handling deficiencies. The company plans to report third-quarter results Oct. 27.
- manilatimes.net11:57
**media[1266077]**- New Studies Expand Cesalatamig into Biomarker-driven Precision
- manilatimes.net12:05
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment...
- manilatimes.net12:06
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ('Calidi” or 'the Company”), a biotechnology company pioneering the development of targeted genetic medicines, announced that it will be presenting two posters at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026. The presentations will showcase the Company’s RedTail platform, a systemically delivered virotherapy platform engineered...
- manilatimes.net12:06
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for investigational drug UGN-103 (mitomycin) for intravesical solution for the treatment of adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer...
- manilatimes.net12:06
Groundbreaking 4-year safety and efficacy results:
- manilatimes.net12:06
Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DMPatient improvements observed as early as Week 4 and sustained through 52 weeksLate-breaking oral presentation on Wednesday, November 11th, 9:15 - 9:30 AM ETOctober 19, 2026, 8:00 AM ET
- manilatimes.net12:06
Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT
- manilatimes.net12:06
MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data and program updates for CARDAMYST® (etripamil) nasal spray for its approved PSVT indication and on etripamil nasal spray for an investigational indication will be presented at three upcoming cardiovascular medical meetings:
- manilatimes.net12:06
Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET
- manilatimes.net12:06
FORT LAUDERDALE, Fla., and WEST DES MOINES, Iowa, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Syncromune, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™ an investigational in situ multi-target immunotherapy platform for solid tumors, today announced that updated long-term overall survival (OS) data from a Phase 1 trial of SYNC-T Therapy SV-102 in patients with metastatic prostate cancer will be presented at the European Society for Medical Oncology (ESMO) Congress...
- intelligencer.ca12:12
TORONTO, ONTARIO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to
Tue, 20 October 2026
5 reports- indiatimes.com07:06
Three coronary stent models from Meril Life Sciences were withdrawn from the Sri Lankan market due to performance issues. The National Medicines Regulatory Authority conducted an investigation that revealed critical failures. The Central Drugs Standard Control Organisation is auditing manufacturing facilities to address quality concerns. Stricter regulations and robust post-market surveillance measures are necessary to ensure patient safety.
- manilatimes.net08:43
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio
- manilatimes.net08:43
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio
- investegate.co.uk09:15
Comprehensive details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies
- investegate.co.uk09:15
Comprehensive details of regulatory and non regulatory announcements from FTSE 100, 250, AIM and techMARK quoted companies